Immunovant, INC. (IMVT) — 10-K Filings
All 10-K filings from Immunovant, INC.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Immunovant's Net Loss Widens to $304M Amid R&D Push
— May 29, 2025 Risk: high
Immunovant, Inc. reported no revenue for the fiscal year ended March 31, 2025, consistent with its clinical-stage biotechnology status. The company posted a net -
Immunovant Files 2024 10-K
— May 29, 2024 Risk: medium
Immunovant, Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its operations and financial condition. The company, formerly Health Sci
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX